Dr. Rohit Loomba
Claim this profileUniversity of California, San Diego
Studies Nonalcoholic Steatohepatitis
Studies Non-alcoholic Fatty Liver Disease
12 reported clinical trials
12 drugs studied
Area of expertise
1Nonalcoholic Steatohepatitis
Stage I
Stage II
2Non-alcoholic Fatty Liver Disease
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Rohit Loomba is currently running
Non-alcoholic Fatty Liver Disease
for People with HIV
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions associated with fat accumulation that ranges from benign, non-progressive liver fat accumulation to severe liver injury, cirrhosis, and liver failure. NAFLD is the most common liver disease in US adults and the second leading cause for liver transplantation in the US. The natural history of NAFLD in the general population has been well described, with those with non-alcoholic fatty liver (NAFL, or simple steatosis) destined to have rare incidence of hepatic events compared to those with non-alcoholic steatohepatitis (NASH), who are at high risk for future development of cirrhosis, liver cancer and liver failure. The NASH Clinical Research Network (NASH CRN) was established by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in 2002, through the mechanism of RFA-DK-01-025, to further the understanding of diagnosis, mechanisms, progression and therapies of NASH. The NASH CRN effort has resulted in numerous seminal studies in the field. However, NASH CRN studies have systematically excluded persons living with HIV (PLWH), as NAFLD in these persons was thought to be different from that in the general population due to HIV, ART, concomitant medications, and co-infections. This has resulted in major knowledge gaps regarding NAFLD in the setting of HIV. This ancillary study of NAFLD and NASH in Adults with HIV (HIV NASH CRN), HNC 001 goal is to examine the prevalence of hepatic steatosis and NAFLD in a large, multicenter, and multiethnic cohort of PLWH (Steatosis in HIV Study)
Recruiting1 award N/A3 criteria
Nonalcoholic Fatty Liver Disease
for HIV
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions associated with fat accumulation that ranges from benign, non-progressive liver fat accumulation to severe liver injury, cirrhosis, and liver failure. The spectrum of NAFLD encompasses simple nonalcoholic steatosis (nonalcoholic fatty liver \[NAFL\]) and nonalcoholic steatohepatitis (NASH) in which there is evidence of hepatocellular injury and/or fibrosis. NAFLD is the most common liver disease in adults and the second leading cause for liver transplantation in the U.S. The natural history of NAFLD in the general population has been well described. The NASH Clinical Research Network (NASH CRN) was established by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in 2002 to further the understanding of the diagnosis, mechanisms, progression and therapies of NASH. This effort has resulted in numerous seminal studies in the field. However, NASH CRN studies have systematically excluded persons living with HIV (PLWH) , as NAFLD in PLWH was thought to be different from that in the general population due to HIV infection, antiretroviral therapy (ART), concomitant medications and co-infections. This resulted in major knowledge gaps regarding NAFLD in the setting of HIV infection. Thus, the natural history of NAFLD in PLWH is largely unknown. The goal of this ancillary study of NAFLD and NASH in Adults with HIV (HIV NASH CRN), is to conduct a prospective, observational, multicenter study of NAFLD in PLWH (HIV-associated NAFLD).
Recruiting1 award N/A8 criteria
More about Rohit Loomba
Clinical Trial Related5 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Rohit Loomba has experience with
- Placebo
- Semaglutide
- BMS-986263
- Placebo Of HM15211
- HM15211
- Tirzepatide
Breakdown of trials Rohit Loomba has run
Nonalcoholic Steatohepatitis
Non-alcoholic Fatty Liver Disease
Liver Dysfunction
HIV (Human Immunodeficiency Virus)
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rohit Loomba specialize in?
Rohit Loomba focuses on Nonalcoholic Steatohepatitis and Non-alcoholic Fatty Liver Disease. In particular, much of their work with Nonalcoholic Steatohepatitis has involved Stage I patients, or patients who are Stage II.
Is Rohit Loomba currently recruiting for clinical trials?
Yes, Rohit Loomba is currently recruiting for 3 clinical trials in San Diego California. If you're interested in participating, you should apply.
Are there any treatments that Rohit Loomba has studied deeply?
Yes, Rohit Loomba has studied treatments such as Placebo, Semaglutide, BMS-986263.
What is the best way to schedule an appointment with Rohit Loomba?
Apply for one of the trials that Rohit Loomba is conducting.
What is the office address of Rohit Loomba?
The office of Rohit Loomba is located at: University of California, San Diego, San Diego, California 92103 United States. This is the address for their practice at the University of California, San Diego.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.